Single Cell Analysis Market to be driven by Increased government support for cell-based research, technological developments are expected to Grow at a CAGR of 15.80% during the forecast period 2023 to 2032

Market Research Future (MRFR) has published a cooked research report on the “Single Cell Analysis Market” that contains information from 2018 to 2032. The single-cell analysis market is estimated to register a CAGR of 15.80% during the forecast period of 2023 to 2032.

Market Highlights

The single-cell analysis market is accounted to register a CAGR of 15.80% during the forecast period and is estimated to reach USD 12.36 billion by 2032.

The number of single-cell analyses is growing as it is anticipated that the availability of cutting-edge diagnostic technologies will enable the diagnosis and treatment of patients more accurately, which will propel the global single-cell analysis market. Furthermore, technological advancements in single-cell analysis have increased the pharmaceutical and biotechnology industries. The increasing focus on customized therapy, the rising incidence of cancer, and the potential benefits of stem cell research all contribute to the expansion of the single-cell analysis industry. Single-cell analysis products' prohibitively high prices are a major barrier for developing-world consumers and research institutes.

Key Players:

MRFR recognizes the following companies as the key players in the single-cell analysis market -DOLOMITE BIO, Becton, Dickinson and Company, DIASORIN GROUP (LUMINEX CORPORATION), Merck KGaA, BGI GENOMICS CO. LTD, Danaher Corporation, Thermo Fisher Scientific, Inc., BERKLEY LIGHTS INC, TAKARA HOLDINGS INC, OXFORD NANAOPORE TECHNOLOGIES, STANDARD BIOTOOLS (Fluidigm Corporation), Illumina, Inc., Sartorius AG, QIAGEN N.V, Agilent Technologies, Inc., 10x Genomics, and Bio-Rad Laboratories.

Segment Analysis

The single-cell Analysis market has been segmented based on product, techniques, end user, and application.

On the basis of product, the market is segmented into consumables and instruments. The consumables segment was attributed to holding the largest market share in 2022 because there is a persistent demand for test consumables and reagents, the prevalence of target diseases is growing, and product usability is high.

Based on techniques, the single-cell analysis market has been segmented into flow cytometry, next-generation sequencing (NGS), polymerase chain reaction (PCR), mass spectrometry, and others. The next-generation sequencing (NGS) segment was expected to hold market dominance in 2022 due to a surge in genome mapping studies, an increase in next-generation sequencing applications, rising healthcare costs, and improved sequencing platform technology.

Based on end users, the single-cell analysis market has been segmented into academic & research laboratories, biotechnology & pharmaceutical companies, and others. The biotechnology & pharmaceutical companies segment was expected to hold market dominance in 2022 because the use of single-cell analysis by biotechnology and pharmaceutical firms has been facilitated by technological developments such as the usage of microfluidics in the creation of next-generation treatments.

Based on application, the single-cell analysis market has been segmented into oncology, immunology, neurology, stem cell, non-invasive prenatal diagnosis, in-vitro fertilization (IVF), and others. The oncology segment was expected to hold the top market share in 2022 because cancer is becoming more common. Additionally, single-cell analysis demonstrated efficacy for earlier detection of cancer cells, propelling the development of this market segment.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Single Cell Analysis Market Research Report

Regional Analysis

The single-cell analysis market, based on region, has been divided into North America, Europe, Asia-Pacific, and Rest of the World. North America consists of the US and Canada. The European Single Cell Analysis market comprises Germany, France, the UK, Italy, Spain, and the Rest of Europe. The Single Cell Analysis market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the Rest of Asia-Pacific. The Rest of the World Single Cell Analysis market comprises the Middle East, Africa, and Latin America.

The North American regional sector maintained the largest market share for single-cell analysis. This increase is attributed to expanding research and development of the single-cell 6analysis, increased industry cooperation, new tools, and a burgeoning biotech and pharmaceutical sector. Multiple government initiatives undertaken in recent years have helped boost the single-cell analysis market in the region.

Moreover, the European market has been persistently growing over the forecast period. The demand for single-cell analysis is driven by the growing healthcare infrastructure, an aging population, and positive reimbursement policies in healthcare all contribute to the expansion of this industry.

Additionally, due to technology advancements, the availability of skilled professionals, the proliferation of government funding schemes, the growing public consciousness about the cost of healthcare, and the rapid adoption of cutting-edge analytical tools and methods. The region also benefits from a growing middle class and improved healthcare infrastructure. Asia Pacific is anticipated to experience the quickest growth over the forecast period.

Furthermore, the Rest of the World's single-cell analysis market is divided into the Middle East, Africa, and Latin America. This growth is attributed to the region's increasing disposable income and rapid advancements in healthcare infrastructure, which have boosted the need for cutting-edge diagnostic tools, which are all contributing factors to the market expansion.

Key Findings of the Study

• The single-cell analysis market is expected to reach USD 12.36 billion by 2032, at a CAGR of 15.80% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market due to technology advancements, the availability of skilled professionals, the proliferation of government funding schemes, the growing public consciousness about the cost of healthcare, and the rapid adoption of cutting-edge analytical tools and methods. The region also benefits from a growing middle class and improved healthcare infrastructure.


• Based on product, the consumables segment was attributed to holding the largest market in 2022.


• DOLOMITE BIO, Becton, Dickinson and Company, DIASORIN GROUP (LUMINEX CORPORATION), Merck KGaA, BGI GENOMICS CO. LTD, Danaher Corporation, Thermo Fisher Scientific, Inc., BERKLEY LIGHTS INC, TAKARA HOLDINGS INC, OXFORD NANAOPORE TECHNOLOGIES, STANDARD BIOTOOLS (Fluidigm Corporation), Illumina, Inc., Sartorius AG, QIAGEN N.V, Agilent Technologies, Inc., 10x Genomics, and Bio-Rad Laboratories.